Form 4: Celldex Therapeutics CEO Granted Significant Stock Options Under Equity Incentive Plan

Celldex Therapeutics, Inc. President and CEO, Anthony S. Marucci, was granted 300,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Anthony S. Marucci, President & CEO and Director of Celldex Therapeutics, Inc. (CLDX), was granted 300,000 incentive stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $19.53 per share.
• The options were granted under the Issuer's 2021 Omnibus Equity Incentive Plan.
• The options begin vesting on June 5, 2026, with 25% vesting on that date, and the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Mr. Marucci directly beneficially owns 300,000 derivative securities (incentive stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as the option grant aligns management's interests with shareholders and is a standard, expected compensation event, indicating stability in executive incentives. It does not introduce new negative information.

Positives

• The grant of incentive stock options aligns the interests of the President & CEO with those of the shareholders, as the options gain value only if the stock price increases above the exercise price.
• This is a standard practice in executive compensation, indicating continued commitment to the company's long-term performance.

Negatives

• While not an immediate negative, the future exercise of these options could lead to dilution of existing shares, although this is a common aspect of equity compensation plans.

Future Outlook

The vesting schedule of the options indicates a long-term incentive structure for the CEO, aligning his future compensation with the company's performance over the next four years.

Industry Context

The granting of stock options to key executives is a common and widely accepted practice in the biotechnology and pharmaceutical industries, serving as a primary mechanism for long-term incentive compensation and aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule and the use of an omnibus equity incentive plan, is consistent with typical executive compensation practices observed across the biotechnology and broader public company landscape.
• Comparable companies in the biotech sector frequently utilize similar equity-based incentives to attract, retain, and motivate top talent, linking executive performance directly to stock price appreciation.

Corporate Governance

Related Party Transactions

• Grant of 300,000 incentive stock options to Anthony S. Marucci, President & CEO and Director, by Celldex Therapeutics, Inc. under its 2021 Omnibus Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The option grant aims to align the CEO's financial incentives with shareholder returns, potentially leading to increased efforts to boost stock performance.
• Employees: While specific to the CEO, such grants are part of a broader compensation philosophy that can influence overall employee morale and retention strategies.

Next Steps

• The options will vest over a four-year period, with 25% vesting on June 5, 2026, and the remainder vesting quarterly over the subsequent 12 quarters.

Key Dates

Keywords

Celldex Therapeutics, CLDX, stock options, incentive stock option, executive compensation, Form 4, insider transaction, equity incentive plan, Anthony S. Marucci